Proposal for Handling Central Nervous System Symptoms Caused by Lorlatinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Proposal for Handling Central Nervous System Symptoms Caused by Lorlatinib

Published:2024-04-20 Issue:2 Volume:64 Page:83-88
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Kubota Kaoru¹,Yanagitani Noriko²,Ichihara Eiki³,Ohkubo Tsubasa⁴,Akechi Tatsuo⁵

Affiliation:

1. Clinical Oncology Division, Respiratory Care Clinic, Nippon Medical School

2. Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research

3. Center for Clinical Oncology, Okayama University Hospital

4. Medical Affairs, Oncology, Pfizer Japan Inc.

5. Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences

Publisher

Japan Lung Cancer Society

Link

https://www.jstage.jst.go.jp/article/haigan/64/2/64_83/_pdf

Reference9 articles.

1. 1. ファイザー株式会社. ローブレナ^Ⓡ錠25 mg/100 mg添付文書. 2022年6月改訂 (第4版).

2. 2. Sørensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol. 1988; 6: 1474-1480.

3. 3. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020; 383: 2018-2029.

4. 4. Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2022; 11: 354-366.

5. 5. Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022; 40: 3593-3602.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3